We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » STUDY: PARENTERAL PENICILLIN MAY HAVE NEGATIVE EFFECT ON SOME CHILDREN WITH MENINGOCOCCAL DISEASE

STUDY: PARENTERAL PENICILLIN MAY HAVE NEGATIVE EFFECT ON SOME CHILDREN WITH MENINGOCOCCAL DISEASE

June 2, 2006

The administration of parenteral penicillin to children with suspected meningococcal disease may increase the rate of morbidity if the drugs are given before hospital admission, according to a study published in the British Medical Journal.

In the trial, which was conducted in England, Wales, and Northern Ireland, between 1997 and 1999, 158 children aged 1 to 16 years were profiled. For all the study subjects, a general practitioner had made the diagnosis of meningococcal disease before hospital admission. Twenty-six of these patients died and 132 survived; 57 survivors experienced complications. Injections of penicillin were given to 105 of the patients. Administration of parenteral penicillin by the general practitioners, found the study, was associated with an increased ratio of death, or increased complications in survivors. Children who received penicillin had more severe disease symptoms upon admission. Severity did not differ significantly with time taken to reach the hospital.

In an editorial accompanying the study, Duncan Keeley, a physician at The Health Centre in Thame, England, agreed that antibiotics may increase severity by liberating endotoxin during bacteriolysis — dissolution of bacteria — but adds that researchers observed no evidence of this.

The monitoring of vital signs and starting IV fluids "may be more important for improving survival than administering parenteral penicillin," added Keely.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing